About the Authors
- Praveen Papareddy
-
* E-mail: praveen.papareddy@med.lu.se
Affiliation Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Biomedical Center, Lund, Sweden
- Martina Kalle
-
Affiliation Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Biomedical Center, Lund, Sweden
- Ole E. Sørensen
-
Affiliation Division of Infection Medicine, Department of Clinical Sciences, Lund University, Biomedical Center, Lund, Sweden
- Katarina Lundqvist
-
Affiliation Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Biomedical Center, Lund, Sweden
- Matthias Mörgelin
-
Affiliation Division of Infection Medicine, Department of Clinical Sciences, Lund University, Biomedical Center, Lund, Sweden
- Martin Malmsten
-
Affiliation Department of Pharmacy, Uppsala University, Uppsala, Sweden
- Artur Schmidtchen
-
Affiliation Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Biomedical Center, Lund, Sweden
Competing Interests
Drs. Malmsten and Schmidtchen are co-founders of, and own shares in XImmune AB, a company developing peptides for anti-infective treatment. The TFPI-2 peptide EDC34 is included in a patent application of the company. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: PP AS. Performed the experiments: PP MK OS KL M. Mörgelin M. Malmsten. Analyzed the data: PP AS. Contributed reagents/materials/analysis tools: KL M. Malmsten. Wrote the paper: PP AS.